No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
Yu Kyong Kim,1,* Jun Gi Hwang,1,* Min Kyu Park1,2 1Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju, Republic of Korea; 2Department of Pharmacology and Clinical Pharmacology, Dong-A University College of Medicine, Dong-A Un...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-04-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1818598371876667392 |
|---|---|
| author | Kim YK Hwang JG Park MK |
| author_facet | Kim YK Hwang JG Park MK |
| author_sort | Kim YK |
| collection | DOAJ |
| description | Yu Kyong Kim,1,* Jun Gi Hwang,1,* Min Kyu Park1,2 1Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju, Republic of Korea; 2Department of Pharmacology and Clinical Pharmacology, Dong-A University College of Medicine, Dong-A University Hospital, Busan, Republic of Korea*These authors contributed equally to this workCorrespondence: Min Kyu ParkDepartment of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, 776, 1 Sunhwan-ro, Seowon-gu, Cheongju-si, Chungcheongbuk-do, 28644, Republic of KoreaTel +82 43 269 8708Fax +82 43 269 8724Email mk_park@cbnuhctc.comPurpose: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharmacokinetic (PK) drug–drug interactions between empagliflozin and lobeglitazone in healthy subjects.Subjects and Methods: A randomized, open-label, multiple-dose study was conducted in 30 healthy subjects using a three-treatment, six-sequence, three-way crossover design. Subjects received one of the following treatments once daily for 5 days in each period: 25 mg empagliflozin, 0.5 mg lobeglitazone sulfate, or a combination. Serial blood sampling before every dose and up to 24 h after the last dose was performed during each treatment period. The PK parameters were estimated using noncompartmental methods with the plasma empagliflozin and lobeglitazone concentrations. The absence of a PK interaction was construed as the 90% confidence interval (90% CI) of maximum concentration at steady state (Cmax,ss) and area under the concentration-time curve over the dosing interval (AUCtau) for combination therapy-to-monotherapy ratios within the limits of 0.80– 1.25.Results: The steady-state plasma empagliflozin and lobeglitazone concentration-time profiles of combination therapy and monotherapy were comparable in the 25 subjects who completed the study. Coadministration of empagliflozin with lobeglitazone did not affect empagliflozin PK (with 90% CIs of 0.956– 1.150 and 0.945– 1.133 for Cmax,ss and AUCtau, respectively). Likewise, empagliflozin did not affect lobeglitazone Cmax,ss or AUCtau (with 90% CIs of 0.869– 0.995 and 0.851– 1.018, respectively). All treatment groups tolerated mild adverse events well.Conclusion: The lack of PK interactions between lobeglitazone and empagliflozin in combination therapy, along with their good tolerability, indicates that the two drugs can be coadministered without dose adjustment.Trial Registration Number: NCT02854748, Registered on August 7, 2016.Keywords: clinical trial, antidiabetic drug, pharmacokinetic interaction, thiazolidinedione, type 2 diabetes |
| first_indexed | 2024-12-16T12:02:39Z |
| format | Article |
| id | doaj.art-a818304fe44a4be8bd64be82b635069b |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-16T12:02:39Z |
| publishDate | 2021-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-a818304fe44a4be8bd64be82b635069b2022-12-21T22:32:25ZengDove Medical PressDrug Design, Development and Therapy1177-88812021-04-01Volume 151725173464270No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy SubjectsKim YKHwang JGPark MKYu Kyong Kim,1,* Jun Gi Hwang,1,* Min Kyu Park1,2 1Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju, Republic of Korea; 2Department of Pharmacology and Clinical Pharmacology, Dong-A University College of Medicine, Dong-A University Hospital, Busan, Republic of Korea*These authors contributed equally to this workCorrespondence: Min Kyu ParkDepartment of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, 776, 1 Sunhwan-ro, Seowon-gu, Cheongju-si, Chungcheongbuk-do, 28644, Republic of KoreaTel +82 43 269 8708Fax +82 43 269 8724Email mk_park@cbnuhctc.comPurpose: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharmacokinetic (PK) drug–drug interactions between empagliflozin and lobeglitazone in healthy subjects.Subjects and Methods: A randomized, open-label, multiple-dose study was conducted in 30 healthy subjects using a three-treatment, six-sequence, three-way crossover design. Subjects received one of the following treatments once daily for 5 days in each period: 25 mg empagliflozin, 0.5 mg lobeglitazone sulfate, or a combination. Serial blood sampling before every dose and up to 24 h after the last dose was performed during each treatment period. The PK parameters were estimated using noncompartmental methods with the plasma empagliflozin and lobeglitazone concentrations. The absence of a PK interaction was construed as the 90% confidence interval (90% CI) of maximum concentration at steady state (Cmax,ss) and area under the concentration-time curve over the dosing interval (AUCtau) for combination therapy-to-monotherapy ratios within the limits of 0.80– 1.25.Results: The steady-state plasma empagliflozin and lobeglitazone concentration-time profiles of combination therapy and monotherapy were comparable in the 25 subjects who completed the study. Coadministration of empagliflozin with lobeglitazone did not affect empagliflozin PK (with 90% CIs of 0.956– 1.150 and 0.945– 1.133 for Cmax,ss and AUCtau, respectively). Likewise, empagliflozin did not affect lobeglitazone Cmax,ss or AUCtau (with 90% CIs of 0.869– 0.995 and 0.851– 1.018, respectively). All treatment groups tolerated mild adverse events well.Conclusion: The lack of PK interactions between lobeglitazone and empagliflozin in combination therapy, along with their good tolerability, indicates that the two drugs can be coadministered without dose adjustment.Trial Registration Number: NCT02854748, Registered on August 7, 2016.Keywords: clinical trial, antidiabetic drug, pharmacokinetic interaction, thiazolidinedione, type 2 diabeteshttps://www.dovepress.com/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDTclinical trialantidiabetic drugpharmacokinetic interactionthiazolidinedionetype 2 diabetes |
| spellingShingle | Kim YK Hwang JG Park MK No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects Drug Design, Development and Therapy clinical trial antidiabetic drug pharmacokinetic interaction thiazolidinedione type 2 diabetes |
| title | No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects |
| title_full | No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects |
| title_fullStr | No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects |
| title_full_unstemmed | No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects |
| title_short | No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects |
| title_sort | no relevant pharmacokinetic drug ndash drug interaction between the sodium glucose co transporter 2 inhibitor empagliflozin and lobeglitazone a peroxisome proliferator activated receptor gamma agonist in healthy subjects |
| topic | clinical trial antidiabetic drug pharmacokinetic interaction thiazolidinedione type 2 diabetes |
| url | https://www.dovepress.com/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT kimyk norelevantpharmacokineticdrugndashdruginteractionbetweenthesodiumglucosecotransporter2inhibitorempagliflozinandlobeglitazoneaperoxisomeproliferatoractivatedreceptorgammaagonistinhealthysubjects AT hwangjg norelevantpharmacokineticdrugndashdruginteractionbetweenthesodiumglucosecotransporter2inhibitorempagliflozinandlobeglitazoneaperoxisomeproliferatoractivatedreceptorgammaagonistinhealthysubjects AT parkmk norelevantpharmacokineticdrugndashdruginteractionbetweenthesodiumglucosecotransporter2inhibitorempagliflozinandlobeglitazoneaperoxisomeproliferatoractivatedreceptorgammaagonistinhealthysubjects |